Copayments Will Likely Increase for Remicade Therapy in the Treatment of Crohn's Disease
Posted on: Monday, 22 May 2006, 12:01 CDT
WALTHAM, Mass., May 22 /PRNewswire/ -- Decision Resources, Inc., one of the world's leading research and advisory firms for pharmaceutical and health care issues, finds that HMOs already use or are likely to use specific cost control measures relative to Remicade therapy for the treatment of Crohn's Disease. Nearly 60% of HMO pharmacy directors surveyed indicate that they already require authorization prior to initiation of Remicade therapy as a cost control measure, while 40% already require a step-care approach to Remicade therapy. According to the new PhysicianForum report entitled Crohn's Disease: Physician and Payer Acceptance of Early Biologics Use, many HMOs indicate that increases in coinsurance or patient copayments are also somewhat likely.
Trying and failing other therapies is one measure that HMOs have taken to relieve the cost burden of Remicade.
"Approximately half of HMO pharmacy directors say that their health plans require Crohn's disease patients to try and fail therapy with conventional agents prior to Remicade use," says Stephanie Krebs, analyst at Decision Resources. "Oral aminosalicylates, oral coricosteroids, and topical aminosalicylates are the agents HMO pharmacy directors cite as the conventional agents that must be tried and failed prior to the initiation of Remicade therapy."
Crohn's Disease: Physician and Payer Acceptance of Early Biologics Use is based on a U.S. survey of 31 managed care pharmacy and medical directors and 116 gastroenterologists. Their responses were compared to assess similarities and differences of opinion regarding clinical, economic, and scientific factors.
About PhysicianForum
PhysicianForum is a primary research service from Decision Resources that offers access to high volume-prescribing physicians, specialists, and managed care organization representatives in the United States; analysis of events and survey participants' responses to them; insight into prescribing patterns; and an examination of the implications of events and issues for the pharmaceutical market.
About Decision Resources
Decision Resources, Inc. (http://www.decisionresources.com/) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Elizabeth Marshall Decision Resources, Inc. 781-296-2563 emarshall@dresources.com
Decision Resources, Inc.
CONTACT: Elizabeth Marshall of Decision Resources, Inc.,+1-781-296-2563, or emarshall@dresources.com
Web site: http://www.decisionresources.com/
Source: PRNewswire
Related Articles
- Sanofi-aventis Partners With the Hispanic Community in San Antonio to Increase Health Awareness, Access to Resources and Help Improve Patient Care
- Sanofi-aventis Partners with the African American Community in Newark to Increase Health Awareness, Access to Resources and Help Improve Patient Care
- Sanofi-aventis Partners with the Hispanic Community in Bronx to Increase Health Awareness, Access to Resources and Help Improve Patient Care
- Sanofi-aventis Partners with the African American Community in Memphis to Increase Health Awareness, Access to Resources and Help Improve Patient Care
- Sanofi-aventis Partners with the African American Community in Baltimore to Increase Health Awareness, Access to Resources and Help Improve Patient Care
- An Obesity Drug Pipeline Report: The Development of Therapies for a Complex Disease
- Ten Communities Selected to Receive Grants From the National Association of Chronic Disease Directors and the YMCA of the USA to Combat Obesity and Chronic Disease
- Diagnosis: Treatments: Leading Products - Disease and Therapy Review: Alzheimers Disease
- Nephrotic Syndrome Complicating -Glucosidase Replacement Therapy for Pompe Disease
 |
 |
User Comments (0)
RSS Feeds